These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33579588)

  • 1. Between Emergency Department Visits: The Role of Harm Reduction Programs in Mitigating the Harms Associated With Injection Drug Use.
    Macias-Konstantopoulos W; Heins A; Sachs CJ; Whiteman PJ; Wingkun NG; Riviello RJ
    Ann Emerg Med; 2021 May; 77(5):479-492. PubMed ID: 33579588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of harm reduction for injection drug use: A clinical and public health ethics analysis.
    Vearrier L
    Dis Mon; 2019 May; 65(5):119-141. PubMed ID: 30600096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harm Reduction: Front Line Public Health.
    Stancliff S; Phillips BW; Maghsoudi N; Joseph H
    J Addict Dis; 2015; 34(2-3):206-19. PubMed ID: 26080038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia.
    Harris RE; Richardson J; Frasso R; Anderson ED
    Int J Drug Policy; 2018 Feb; 52():56-61. PubMed ID: 29241143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing risk and presentation of overdose associated with consumption of street drugs at a supervised injection site in Vancouver, Canada.
    Notta D; Black B; Chu T; Joe R; Lysyshyn M
    Drug Alcohol Depend; 2019 Mar; 196():46-50. PubMed ID: 30665151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combination approach on harm reduction programs: the Taiwan experience.
    Lin T; Chen CH; Chou P
    Harm Reduct J; 2016 Jul; 13(1):23. PubMed ID: 27377896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study.
    Kennedy MC; Hayashi K; Milloy MJ; Wood E; Kerr T
    PLoS Med; 2019 Nov; 16(11):e1002964. PubMed ID: 31770391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmet needs and harm reduction preferences of syringe services program participants: differences by co-use of illicit opioids and methamphetamine.
    Sun R; Sauda TH; Hoopsick RA
    Harm Reduct J; 2024 Jun; 21(1):119. PubMed ID: 38890736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in public order after the opening of an overdose monitoring facility for people who inject drugs.
    León C; Cardoso LJP; Johnston S; Mackin S; Bock B; Gaeta JM
    Int J Drug Policy; 2018 Mar; 53():90-95. PubMed ID: 29294417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The implementation of overdose prevention sites as a novel and nimble response during an illegal drug overdose public health emergency.
    Wallace B; Pagan F; Pauly BB
    Int J Drug Policy; 2019 Apr; 66():64-72. PubMed ID: 30708237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
    Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
    Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harm reduction in the USA: the research perspective and an archive to David Purchase.
    Des Jarlais DC
    Harm Reduct J; 2017 Jul; 14(1):51. PubMed ID: 28747189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High uptake of naloxone-based overdose prevention training among previously incarcerated syringe-exchange program participants.
    Barocas JA; Baker L; Hull SJ; Stokes S; Westergaard RP
    Drug Alcohol Depend; 2015 Sep; 154():283-6. PubMed ID: 26143300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. French People's positions on supervised injection facilities for drug users.
    Munoz Sastre MT; Kpanake L; Mullet E
    Subst Abuse Treat Prev Policy; 2020 Oct; 15(1):79. PubMed ID: 33054832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia.
    Salmon AM; van Beek I; Amin J; Kaldor J; Maher L
    Addiction; 2010 Apr; 105(4):676-83. PubMed ID: 20148794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'It's our safe sanctuary': Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario.
    Foreman-Mackey A; Bayoumi AM; Miskovic M; Kolla G; Strike C
    Int J Drug Policy; 2019 Nov; 73():135-140. PubMed ID: 31654936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The place of syringe exchange programs in reducing harm in Canadian prisoners].
    Orsi MM; Brochu S
    Can J Public Health; 2009; 100(1):29-31. PubMed ID: 19263972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?
    Bonny-Noach H
    Isr J Health Policy Res; 2019 Oct; 8(1):75. PubMed ID: 31619286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supervised Injection Facilities as Harm Reduction: A Systematic Review.
    Levengood TW; Yoon GH; Davoust MJ; Ogden SN; Marshall BDL; Cahill SR; Bazzi AR
    Am J Prev Med; 2021 Nov; 61(5):738-749. PubMed ID: 34218964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.
    Bouvier BA; Elston B; Hadland SE; Green TC; Marshall BD
    Harm Reduct J; 2017 Feb; 14(1):13. PubMed ID: 28219388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.